Top 10 Healthcare Technology Stocks For 2015

Top 10 Healthcare Technology Stocks For 2015: MannKind Corporation(MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia. Its lead product candidate, AFREZZA Inhalation Powder, an ultra rapid-acting insulin that is in Phase III clinical trials for the treatment of diabetes for the control of hyperglycemia. The company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials for the treatment of adults with type 1 or type 2 diabetes; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases. In addition, its products include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; MKC1106-PP, a Phase I clinical trials product for diverse tumor types, metastatic disease, and/or progressive and refractory disease; and MKC180, an obesity compound and MKC1106-NS , a cancer immunotherapy product that are in preclinical trials. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

Advisors' Opinion:

• [By Damian Illia]

  Based in Valencia, Calif., and founded in 1991, MannKind Corporation (MNKD) is a development stage biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapeutic products for diseases like diabetes. The company's lead and only late stage pipeline candidate for this year is Afrezza, an inhalation powder which is an ultra insulin therapy for the treatment of adults with type 1 or type 2 diabetes to control their hyperglycemia. Currently, it is in late-stage clinical trials and a final decision from the U.S. regulatory body is expected by April 15, 2014. There is great concern revolving around this decision, as MannKind has already received two complete response letters (CRL) for Afrezza ! from the FDA, and it was requested to conduct two phase III trials with the next-generation inhaler. Further delay in approval or another setback related to this candidate could be a great danger for the company. Over and probably excessive depende nce on Afrezza as the company discontinued any other reasearch in other candidates is something to worry about. The company has generated no revenue last year round and its shares have experienced a total annual loss of $0.64 so far.

• [By Brian Orelli]

  Last clinical trials!
  MannKind (NASDAQ: MNKD  ) has been developing its inhaled insulin product Afrezza for years. The FDArejectedthe drug-device combo in 2010, requesting additional information on the clinical utility of Afrezza.

• [By Brian Orelli]

  Anticipation
  MannKind's (NASDAQ: MNKD  ) rise doesn't appear to be due to anything that the biotech company has done, but what investors expect the company will do in the future. Specifically, investors are anticipating the release of data this summer for its phase 3 trials testing inhaled insulin Afrezza.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-healthcare-technology-stocks-for-2015.html